NEWS & EVENTS January 2014 ISCORT The annual meeting of the Israeli Society for Clinical Oncology and Radiation therapy, ISCORT 13, will take place from 14-18 January 2014 at the Dan Eilat Hotel. Lectures from world leading experts will present their most important innovations of the past year. The Israeli Society for Clinical Oncology and Radiation therapy MEDICA at 20-23 Nov. 2013 in Düsseldorf, Germany Meet our representative at the world‘s largest medical marketplace annually organized in Düsseldorf, Germany. MEDICA Nov. 2013 Düsseldorf July 2013 The company opened new clinical sites to recruit carcinoma and advanced adenoma patients in collaboration with the departments of Gastroenterology at the Humanitas Clinical and Research Center, Milano and at Clalit Health Services HMO, Jerusalem. Humanitas Research Hospital (Milan) Clalit Health Services 29-30 June 2013 PMWC -Personalized Medicine World conference 2013 The 12th National Life Science & Technology Week June. 10-12, Tel Aviv, Israel. Personalized Medicine World conference 2013 10-12 June 2013 IATI-BioMed Israel 2013 The 12th National Life Science & Technology WeekIATI-Biomed Israel 2013 13-17 October 2012 Jerusalem ISOBM congress 2012 The 40th congress of the International Society of Oncology and Biomarkers. Oct. 13-17, Jerusalem, Israel. Jerusalem ISOBM congress 2012 21-23 May 2012 Biomarker World Congress 2012 May 21-23, Philadelphia. The Biomarker World Congress 2012 5 April 2012 BioMarCare has received a final approval from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation to support BioMarCare’s partnership with Ariadne Inc. by granting approximately 900 thousand dollars for the collaboration. BioMarCare's $900k BIRD grant approved 27 March 2012 BioMarCare closes strategic investment by MicroMedic, a Bio-Light subsidiary. A Strategic Investment in BioMarCare Technologies Inc. Nov 2011 BioMarCare has received its second consecutive grant approval for a project with a total budget of over 1.5 M NIS of which 60% will be funded by the OCS. The project approved is for the research and development of Diagnostic kits based on PAR biomarkers for cancer identification. Press Release_grant approval_OCS